Scalper1 News
Specialty drugmaker Horizon Pharma (HZNP) jumped in Friday trade after it pounded Wall Street’s Q3 estimates and raised its guidance. Horizon’s adjusted earnings soared 268% over the year-earlier quarter to 70 cents a share, some 30 cents above analysts’ consensus, according to Thomson Reuters. Sales tripled to $226.4 million, more than $40 million past consensus. Horizon added $85 million to its full-year revenue guidance, now $750 million to Scalper1 News
Scalper1 News